Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0030794 (
pelvic pain
)
4,056
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
From August 1988-June 1989, 983 physicians participated in a phase IV trial by following 7759 women using the monophasic oral contraceptive (OC),
Demulen
1/35 (1 mg ethynodiol diacetate and 35 ug ethinyl estradiol) to evaluate its efficacy and safety. The total number of cycles for the study stood at 21,440. In addition, the total woman-years stood at 1787. Only 6382 patients could be evaluated for safety. 4.4% of the patients had adverse reactions to the OC, but only 1.7% of all patients stopped taking it. The leading side effects included nausea (67 cases), headache (45), amenorrhea (42), emotional changes (30), breast pain (19), dysmenorrhea (12), and 11 cases of weight gain, abdominal/
pelvic pain
, and bloating. Of the 280 reported adverse reactions, only 87 (31%) were considered severe. The leading serious adverse reactions were depression (10) and hypertension (6). Only 5412 patients could be used to determine efficacy. The physicians initially reported 121 (2.2%) pregnancies during the study. The researchers learned that 33 of the 84 returned 2nd questionnaires (response rate, 70%) reported that the women conceived after enrollment but before taking the OC. 36 conceived while taking it, but 8 did not take it daily. Noncompliance may have contributed to pregnancy for the remaining 28 cases. Therefore the 36 confirmed pregnancies made for a failure rate of .7%. 85.7% of the pregnancies happened in the 1st 3 months of taking the OC. Either patient noncompliance or true medication failure accounted for treatment failure. Therefore it is important for physicians to instruct patients on how to take OCs correctly.
...
PMID:Efficacy and safety of ethynodiol diacetate, 1 mg, with ethinyl estradiol, 35 micrograms, with an emphasis on contraceptive efficacy. A phase IV trial. 204 81
The 1st known case of an IUD breaking at the eye, rather than at the thread, leaving the retrieved thread intact, is presented. The woman was a 25-year primipara who had worn an
Ortho
Gynae-T, her 2nd IUD, for 6 months. She presented with complaints of discomfort, requesting IUD removal/ The intact threads were removed without the IUD. The patient developed
pelvic pain
, vaginal bleeding, cervical motion tenderness and adnexal tenderness, while awaiting scheduled laparoscopy. During laparoscopy, the IUD was not felt, and perforation of the anterior fundus occurred on exploration. The IUD was found during laparotomy and removed from the myometrium. The manufacturer of this IUD,
Ortho
Cilag Pharmaceuticals Ltd., has no record of any breakage of the eye of this IUD, nor of any other IUDs. In case of retrieval of an intact thread without the IUD, it is likely that the IUD is embedded or perforated.
...
PMID:An intra-uterine device snapped at the thread insertion. 1228 26
Although adolescent pregnancy and birth rates have been declining since the early 1990s, the rate of intrauterine device (IUD) use in adolescents remain low. IUDs are a highly effective contraceptive method with a failure rate of less than 1%. There are currently 5 IUDs available and marketed in the United States: the nonhormonal copper-containing IUD (Paragard Copper T380A;
Ortho
-McNeil) and 4 hormonal levonorgestrel-releasing intrauterine systems (LNG-IUDs). IUDs can be used in adolescents, and the LNG-IUD has many noncontraceptive benefits including the treatment of heavy menstrual bleeding, dysmenorrhea,
pelvic pain
/endometriosis, and endometrial hyperplasia/endometrial cancer. In addition, the LNG-IUD is an effective tool for suppression of menses.
...
PMID:Intrauterine Devices: Effective Contraception with Noncontraceptive Benefits for Adolescents. 3158 15